Literature DB >> 33558319

Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Von Vergel L Torres1, Carrie F Coggon1, Timothy J Wells2.   

Abstract

Antibody-dependent enhancement (ADE) of viral disease has been demonstrated for infections caused by flaviviruses and influenza viruses; however, antibodies that enhance bacterial disease are relatively unknown. In recent years, a few studies have directly linked antibodies with exacerbation of bacterial disease. This ADE of bacterial disease has been observed in mouse models and human patients with bacterial infections. This antibody-mediated enhancement of bacterial infection is driven by various mechanisms that are disparate from those found in viral ADE. This review aims to highlight and discuss historic evidence, potential molecular mechanisms, and current therapies for ADE of bacterial infection. Based on specific case studies, we report how plasmapheresis has been successfully used in patients to ameliorate infection-related symptomatology associated with bacterial ADE. A greater understanding and appreciation of bacterial ADE of infection and disease could lead to better management of infections and inform current vaccine development efforts.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Gram-negative bacteria; Gram-positive bacteria; antibody; capsular polysaccharide; enhancement; lipopolysaccharide; proteases

Year:  2021        PMID: 33558319      PMCID: PMC8090947          DOI: 10.1128/IAI.00054-21

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  142 in total

1.  Naturally-acquired immunity to Neisseria meningitidis group A.

Authors:  Jacob Amir; Lesile Louie; Dan M Granoff
Journal:  Vaccine       Date:  2005-01-11       Impact factor: 3.641

2.  The Bactericidal Action of Bovine Blood for Brucella and Its Possible Significance.

Authors:  I F Huddleson; E E Wood; A R Cressman; G R Bennett
Journal:  J Bacteriol       Date:  1945-09       Impact factor: 3.490

Review 3.  The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.

Authors:  Daniele Provenzano; Pavol Kovác; William F Wade
Journal:  Microbiol Immunol       Date:  2006       Impact factor: 1.955

4.  Role of antilipopolysaccharide antibodies in serum bactericidal activity against Salmonella enterica serovar Typhimurium in healthy adults and children in the United States.

Authors:  Estela Trebicka; Susan Jacob; Waheed Pirzai; Bryan P Hurley; Bobby J Cherayil
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

5.  Isolation and characterization of a serum antibactericidal factor.

Authors:  P W Taylor
Journal:  Clin Sci       Date:  1972-11       Impact factor: 6.124

6.  Serum bactericidal activity in patients with upper and lower urinary tract infections.

Authors:  P E Gower; P W Taylor; K G Koutsaimanis; A P Roberts
Journal:  Clin Sci       Date:  1972-07       Impact factor: 6.124

7.  The antigen composition of ECHO type 6 virus studied by immunodiffusion and immunoelectrophoresis.

Authors:  M Forsgren
Journal:  Acta Pathol Microbiol Scand       Date:  1966

8.  IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms.

Authors:  J M Griffiss; D K Goroff
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase.

Authors:  T Bainbridge; R B Fick
Journal:  J Lab Clin Med       Date:  1989-12

10.  Nature and Heterogeneity of the Antigens of Neisseria gonorrhoeae Involved in the Serum Bactericidal Reaction.

Authors:  A A Glynn; M E Ward
Journal:  Infect Immun       Date:  1970-08       Impact factor: 3.441

View more
  5 in total

1.  Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis.

Authors:  Amy Pham; Emma L Ledger; Carrie F Coggon; Ian R Henderson; David W Reid; Scott C Bell; Daniel J Smith; Timothy J Wells
Journal:  Infect Immun       Date:  2021-08-30       Impact factor: 3.441

Review 2.  Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?

Authors:  Isabella Zanella; Melania Degli Antoni; Valentina Marchese; Francesco Castelli; Eugenia Quiros-Roldan
Journal:  Int Immunopharmacol       Date:  2022-06-13       Impact factor: 5.714

3.  Can we decloak how infections drive complications after lung transplantation?

Authors:  Hrishikesh S Kulkarni; Erika D Lease
Journal:  J Heart Lung Transplant       Date:  2021-05-29       Impact factor: 13.569

Review 4.  Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.

Authors:  Cillian Gartlan; Tom Tipton; Francisco J Salguero; Quentin Sattentau; Andrew Gorringe; Miles W Carroll
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

5.  Is Antibody-Dependent Enhancement of Trypanosoma cruzi Infection Contributing to Congenital/Neonatal Chagas Disease?

Authors:  Yves Carlier; Carine Truyens; Eric Muraille
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.